Get the Stockscreener App
27.87
2.86%
-0.82
Avidity Biosciences Inc stock is traded at $27.87, with a volume of 1.15M.
It is down -2.86% in the last 24 hours and up +12.38% over the past month.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
See More
Previous Close:
$28.69
Open:
$29
24h Volume:
1.15M
Relative Volume:
0.77
Market Cap:
$3.88B
Revenue:
$10.12M
Net Income/Loss:
$-280.49M
P/E Ratio:
-9.6436
EPS:
-2.89
Net Cash Flow:
$-188.51M
1W Performance:
-13.45%
1M Performance:
+12.38%
6M Performance:
-40.35%
1Y Performance:
+2.84%
1-Day Range:
$27.80
$30.25
1-Week Range:
$25.57
$32.70
52-Week Range:
$21.51
$56.00
Avidity Biosciences Inc Stock (RNA) Company Profile
Name
Avidity Biosciences Inc
Sector
Industry
Phone
858-401-7900
Address
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Compare RNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
27.87 | 3.88B | 10.12M | -280.49M | -188.51M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | Citigroup | Buy |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-20-24 | Initiated | H.C. Wainwright | Buy |
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Sep-24-24 | Initiated | Goldman | Buy |
| Aug-28-24 | Initiated | Barclays | Overweight |
| May-03-24 | Initiated | BofA Securities | Buy |
| Mar-14-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-22-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-31-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Strong Buy |
| Sep-07-21 | Initiated | Evercore ISI | Outperform |
| Jun-17-21 | Initiated | Needham | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jul-07-20 | Initiated | Cowen | Outperform |
| Jul-07-20 | Initiated | Credit Suisse | Outperform |
| Jul-07-20 | Initiated | SVB Leerink | Outperform |
| Jul-07-20 | Initiated | Wells Fargo | Overweight |
View All
Avidity Biosciences Inc Stock (RNA) Latest News
Avidity Biosciences Announces Upcoming Presentations at 2023 Myo - GuruFocus
Avidity Biosciences (RNA) Receives Buy Rating from Chardan Capital | RNA Stock News - GuruFocus
Avidity Biosciences Reports First Quarter 2025 Financial Results and Recent Highlights - BioSpace
Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
12 Analysts Assess Avidity Biosciences: What You Need To Know - Benzinga
RNA Therapeutics Pioneer Avidity Biosciences Takes Stage at Major Bank of America Healthcare Conference - Stock Titan
Avidity Biosciences to Participate in Upcoming Investor Conference - marketscreener.com
(RNA) Investment Report - news.stocktradersdaily.com
Avidity Biosciences chief program officer sells $190k in stock By Investing.com - Investing.com Nigeria
Avidity Biosciences chief program officer sells $190k in stock - Investing.com
Avidity Biosciences appoints Deloitte as new auditor By Investing.com - Investing.com Canada
Avidity Biosciences appoints Deloitte as new auditor - Investing.com
Press Release Distribution & PR Platform - ACCESS Newswire
Avidity Biosciences' RNA Drug for DM1 Gains Orphan Status in Jap - GuruFocus
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Financial Times
Avidity Biosciences Expands Team with 33 New Hires, Grants $10M+ in Equity Incentives - Stock Titan
Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025 (PR Newswire) - Aktiellt
Avidity’s del-desiran for DM1 named orphan drug in Japan - Muscular Dystrophy News
Beyond The Numbers: 13 Analysts Discuss Avidity Biosciences Stock - Benzinga
Japan grants Avidity’s DM1 drug Orphan status By Investing.com - Investing.com South Africa
Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1 - StreetInsider
Avidity Biosciences Receives Orphan Drug Designation in Japan fo - GuruFocus
Avidity Says Japan Grants Orphan Drug Status to Del-Desiran for Myotonic Dystrophy Type 1 - marketscreener.com
Japan grants Avidity's DM1 drug Orphan status By Investing.com - Investing.com India
Japan grants Avidity's DM1 drug Orphan status - Investing.com
Avidity Biosciences Receives Orphan Drug Designation In Japan For Delpacibart Etedesiran - MarketScreener
Myotonic Dystrophy Pipeline Analysis and Clinical Trials - openPR.com
Avidity Biosciences chief program officer sells shares worth $206,799 - MSN
Avidity Biosciences CFO sells $93,985 in stock - MSN
Avidity Biosciences (RNA): Among Unstoppable Stocks That Could Double Your Money - MSN
Avidity Biosciences’ chief program officer sells $163k in stock - Investing.com India
Avidity Biosciences’ chief program officer sells $163k in stock By Investing.com - Investing.com UK
Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock? - Nasdaq
When the Price of (RNA) Talks, People Listen - news.stocktradersdaily.com
Avidity Biosciences : to Present at the Virtual Chardan 4th Annual Genetic Medicines Conference 2020 - marketscreener.com
Exclusive Look: Avidity Biosciences Reveals Latest Strategy at Needham Healthcare Conference - Stock Titan
Avidity Biosciences’s SWOT analysis: stock poised for growth amid clinical progress - Investing.com India
Cantor Fitzgerald maintains $96 target on Avidity Biosciences stock - Investing.com Australia
Cantor Fitzgerald maintains $96 target on Avidity Biosciences stock By Investing.com - Investing.com Canada
Avidity Biosciences’s SWOT analysis: stock poised for growth amid clinical progress By Investing.com - Investing.com South Africa
Avidity Completes Enrollment in Del-brax Trial's Biomarker Group for Facioscapulohumeral Muscular Dystrophy - MarketScreener
Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy - StreetInsider
Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy – Company AnnouncementFT.com - Financial Times
Major Breakthrough: Avidity's Muscular Dystrophy Drug Achieves Unprecedented Disease Control in Clinical Trial - Stock Titan
11 Best Gene Therapy Stocks to Buy According to Analysts - Insider Monkey
EFG Asset Management North America Corp. Purchases 58,198 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
The Risk/Reward Of Avidity Biosciences And Its 2 Promising Programs (NASDAQ:RNA) - Seeking Alpha
Avidity Biosciences Inc Stock (RNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Avidity Biosciences Inc Stock (RNA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Gallagher Kathleen P. | Chief Program Officer |
May 01 '25 |
Sale |
32.40 |
5,875 |
190,324 |
50,554 |
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):